Showing results (311-320 of 1,420) with videos related to
Sort By:
Pageof 142
Neurology|June 30, 2005
Depression is associated with impairment of ADL, not motor function in Parkinson diseaseSuzanne Holroyd, Lillian J Currie, G Frederick WootenJournal of Forensic Sciences|June 19, 2021
Fatal jellyfish envenoming-Pediatric and geographic vulnerabilitiesMarianne Tiemensma, Bart J Currie, Roger W ByardSystematic Reviews|August 24, 2019
Snakebite associated thrombotic microangiopathy: a protocol for the systematic review of clinical features, outcomes, and role of interventionsTina Noutsos, Bart J Currie, Geoffrey K IsbisterNeurological Research|February 5, 2008
Validity, sensitivity and specificity of the mentation, behavior and mood subscale of the UPDRSSuzanne Holroyd, Lillian J Currie, G Frederick WootenThe Journal of Biological Chemistry|May 2, 2000
Retrovirally mediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitroM G Kinsella, J W Fischer, D P Mason, et al.American Journal of Respiratory Cell and Molecular Biology|March 1, 1993
Alterations in nonhuman primate (M. nemestrina) lung proteoglycans during normal development and acute hyaline membrane diseaseS E Juul, M G Kinsella, T N Wight, et al.The Journal of Biological Chemistry|January 3, 1997
Selective expression and processing of biglycan during migration of bovine aortic endothelial cells. The role of endogenous basic fibroblast growth factorM G Kinsella, C K Tsoi, H T Järveläinen, et al.The Journal of Biological Chemistry|December 5, 1991
Differential expression of small chondroitin/dermatan sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in cultureH T Järveläinen, M G Kinsella, T N Wight, et al.Ciba Foundation Symposium|January 1, 1986
Vascular cell proteoglycans: evidence for metabolic modulationT N Wight, M G Kinsella, M W Lark, et al.Diabetic Medicine : a Journal of the British Diabetic Association|July 20, 2010
Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008C J Currie, J R Peters, M EvansPageof 142